Notably, liraglutide (LG), a glucagon-like peptide 1 (GLP-1) analog, is one of a newly emerged class of anti-obesity drugs that exerts a beneficial effect on obesity and NAFLD (Fang et al. 2020). Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.